Solventum
SOLV
Market cap $12.7B

73.55 USD

-0.22

0.30%

At close Jul 29, 4:00 PM EDT

After hours

73.55

+0.00

0.00%

1 day

-0.30%

5 days

-0.20%

1 month

-3.02%

3 months

11.02%

6 months

-1.28%

Year to date

11.56%

1 year

28.27%

5 years

-8.06%

10 years

-8.06%

About: Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.

Employees: 22,000

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

22% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 11 (+2) [Q1 2025]

14% more capital invested

Capital invested by funds: $7.53B [Q4 2024] → $8.55B (+$1.03B) [Q1 2025]

1.51% more ownership

Funds ownership: 63.6% [Q4 2024] → 65.11% (+1.51%) [Q1 2025]

8% less first-time investments, than exits

New positions opened: 89 | Existing positions closed: 97

3% less funds holding

Funds holding: 923 [Q4 2024] → 891 (-32) [Q1 2025]

40% less repeat investments, than reductions

Existing positions increased: 216 | Existing positions reduced: 361

41% less call options, than puts

Call options by funds: $43.4M | Put options by funds: $73.2M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$87

18%

upside

Avg. target

$95

29%

upside

High target

$103

40%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Patrick Wood	40%upside $103	Overweight Upgraded	15 Jul 2025
Piper Sandler Jason Bednar	18%upside $87	Overweight Upgraded	19 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SOLV published over the past 30 days

Solventum: Appealing Again

Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure from higher costs and separation expenses, organic growth has accelerated and future guidance has improved. Valuation has become compelling after the share price pullback, with sustainable EPS estimated at $5.50-$6.00 and leverage much lower post-divestment.

Solventum: Appealing Again

Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close.

Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

Zacks Investment Research

Is the Options Market Predicting a Spike in Solventum Stock?

Investors need to pay close attention to SOLV stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Solventum Stock?

Solventum Named a Best Company to Work for by U.S. News & World Report

Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's three-phased Transformation Plan ST. PAUL, Minn.

Solventum Named a Best Company to Work for by U.S. News & World Report

Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

ST. PAUL, Minn. , June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m.

Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

Zacks Investment Research

SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?

Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.

SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?

Zacks Investment Research

Solventum (SOLV) Just Overtook the 200-Day Moving Average

Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.

Solventum (SOLV) Just Overtook the 200-Day Moving Average

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Frederick Wise - Stifel, Nicolaus & Company, Inc. Jason Bednar - Piper Sandler & Co. David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Steven Valiquette - Mizuho Securities Operator Good afternoon. My name is Amy [ph] and I will be your conference call operator for today.

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

Solventum Corporation: Cheap, With Caveats

Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration, with a market cap of $11.5 billion. The company recently announced the sale of its Purification and Filtration business to Thermo Fisher at what seems a more than solid price.

Solventum Corporation: Cheap, With Caveats

Zacks Investment Research

Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline

SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.

Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline

See News Rankings

Charts implemented using Lightweight Charts™